Conditions such as CHF and CKD are often characterized by increased circulating Ang II levels and the dose of Ang II used in our study produces a 2.8 fold increase in plasma Ang II [47], consistent with the increase found in patients with CHF and CKD [14], [15], [48], [49]. This evidence concerns the gene AGT and congestive heart failure.